Ross is a partner in the Corporate Technology & Life Sciences team, based in our Cambridge office.

Ross is a lead partner within the firm's Tier 1-ranked Biotechnology practice in Cambridge. His practice involves helping life sciences and technology companies as they progress through their life cycle in all aspects of their growth, capital raising and international expansion. As a sector specialist, Ross focuses on biotech, medical devices and diagnostics within Life Sciences, and with the Tech sector supports companies operating in the capital intensive deep tech space, including quantum computing, artificial intelligence, advanced materials, as well as web3.

Ross has extensive experience of a variety of venture and growth financing, public capital raisings, mergers and acquisitions and general corporate advice. Ross was based out of San Francisco, CA in 2018 – 19 and as a result, he has a particular expertise in transactions with a transatlantic component. He is an English qualified solicitor and registered foreign legal consultant in California.

显示完整简历 隐藏完整简历

The impact of affluence on the next economy

An international study examining the behaviours, motivations and goals of today’s UHNW individuals. 

Read full report

最新新闻和观点

公司/并购与资本市场

The AIM market: guides for US issuers

2022年4月27日

作者

点击此处了解更多
data
Interface - Quantum computing - the next really big thing

The investment landscape in quantum computing

Ross McNaughton looks at the focus for investment in quantum technologies.

2022年3月16日

作者 Ross McNaughton

3 / 4 观点

点击此处了解更多
公司/并购与资本市场

Advising New Science Ventures as lead investor on Paragraf's $60 million Series B funding round

2022年3月4日

作者 Ross McNaughton 以及 Adrian Toutoungi

点击此处了解更多
公司/并购与资本市场

Advising Placid0 on its acquisition by eyecare brand WALDO

2022年2月25日

作者

点击此处了解更多

与我会面: